• Vivos Therapeutics Inc VVOS.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-3.05. The mean expectation of two analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -43 cents to -36 cents per share.

• Revenue rose 13.9% to $3.70 million from a year ago; analysts expected $3.89 million.

• Vivos Therapeutics Inc's reported EPS for the quarter was a loss of 28 cents​.

• The company reported a quarterly loss of $2.81 million.

• Vivos Therapeutics Inc shares had fallen by 27.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for Vivos Therapeutics Inc is $6.30

This summary was machine generated from LSEG data March 31 at 10:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)